Eli Lilly and Company LLY reported fourth-quarter 2024 adjusted earnings per share (“EPS”) of $5.32, which beat the Zacks ...

Eli Lilly and Company ... from its leading drugs Trulicity, Verzenio and Taltz. The company operates in a single business segment: human pharmaceutical products. Eli Lilly has a deep pipeline ...

Over the past six months, Eli Lilly (NYSE: LLY) has underperformed broader equities. While that's not much of an issue in the grand scheme of things, it is still a bit surprising, since the ...

These include drugs like Verzenio, Trulicity, Jardiance, Taltz, Humalog, Cyramza, and Olumiant. Recently, Eli Lilly garnered approval for Kisunla, a treatment for early symptomatic Alzheimer's ...

In this article, we are going to take a look at where Eli ... drugs Trulicity, Verzenio and Taltz. The company operates in a single business segment: human pharmaceutical products. Eli Lilly ...

Eli Lilly's sales growth is coming short of expectations, which is a problem considering its valuation. The company does have a vast lineup and a deep pipeline that go beyond diabetes and obesity.

In this article, we are going to take a look at where Eli Lilly and Company (NYSE:LLY) stands against the other dividend stocks. During a time of great excitement about AI-driven capital gains ...

After years of preparation, Eli Lilly is ... data from the pen, and can link with compatible devices. That includes continuous glucose monitoring systems developed by Lilly's partner Dexcom ...